By: Priya Malhotra, PhD From: bcrf.org Findings may help explain why immunotherapies aren’t effective in certain patients with TNBC BCRF investigator Dr. Xiang Zhang and his colleagues are examining the crosstalk between a breast tumor and the body’s immune system to understand why some cancers do not respond to treatment. He and his team recently published results in Nature Cell …
3 Important Things to Know About Triple-Negative Breast Cancer
By: Elizabeth Sile From: bcrf.org Triple-negative breast cancer (TNBC) is a major focus of BCRF’s annual investment in research. But what is it? About 10 to 15 percent of breast cancer diagnoses are classified as triple-negative, meaning that they lack the three common growth drivers: estrogen and progesterone receptors and the HER2 protein. For patients whose breast cancers express all …
Roswell Park Team Identifies New Cause of Chemotherapy Resistance in Triple-Negative Breast Cancer
Source: Roswell Park Comprehensive Cancer Center From: onclive.com Key Takeaways TNBC is aggressive, often resistant to chemotherapy, and has a poor prognosis, especially with high IMPDH2 expression. IMPDH2 aids in doxorubicin resistance, but its inhibition by drugs like ribavirin and mycophenolic acid can reduce tumor growth. IMPDH2-inhibitor drugs, already FDA-approved for other conditions, show promise in targeting chemo-resistant TNBC. The …
Using Immune Biomarkers to Guide Treatment in TNBC
By: Wayne Kuznar From: medpagetoday.com High levels of immune infiltrates are strongly prognostic for favorable outcomes independently of nodal status in triple-negative breast cancer (TNBC). Tumor-Infiltrating Lymphocytes (TILs) High levels of tumor-infiltrating lymphocytes (TILs), which are easy to obtain and report, indicate an active antitumor immune response, said Roberto Salgado, MD, PhD, of the Peter MacCallum Cancer Centre in Melbourne, …
Researchers develop new approach to predict immunotherapy response in breast cancer patients
Source: Johns Hopkins Medical From: news-medical.net Using computational tools, researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a method to assess which patients with metastatic triple-negative breast cancer could benefit from immunotherapy. The work by computational scientists and clinicians was published Oct. 28 in the Proceedings of the National Academy …
Scientists explore HDAC6 inhibition for breast cancer treatment
By: University of Sharjah From: medicalxpress.com Scientists from the University of Sharjah say they have good news for breast cancer patients, particularly those afflicted with the most aggressive types of the malignant tumor known as triple-negative breast cancer. The study, published in the European Journal of Pharmacology, provides “new ways for the treatment of the special type of breast cancer called triple-negative breast …
Assay Predicts Response to Neoadjuvant Atezolizumab Plus Chemotherapy in TNBC
By: Chris Ryan From: onclive.com Key Takeaways The DetermaIO test identified TNBC patients who benefitted from atezolizumab plus chemotherapy, showing improved pCR rates in IO-positive patients. IO-positive patients had a 69.8% pCR rate with atezolizumab, significantly higher than IO-negative patients, indicating the test’s predictive value. The DetermaIO gene expression test identified patients with early-stage triple-negative breast cancer (TNBC) who benefitted …
DAPK3 emerges as a new regulator of migration of triple-negative breast cancer cells
By: Ana María Rodríguez, Baylor College of Medicine From: medicalxpress.com Triple-negative breast cancer (TNBC) is the subtype of breast cancer that is the hardest to treat. TNBC patients account for more than 20,000 cases of this condition annually in the U.S. alone. They experience worse outcomes than patients with other breast cancer subtypes—their five-year mortality rate is about 40%. The …
Researchers develop mechanism that predicts severity of aggressive form of breast cancer
By: Huntsman Cancer Institute From: medicalxpress.com Scientists at Huntsman Cancer Institute at the University of Utah (the U), the National Cancer Institute-designated cancer center for the Mountain West, have made a significant breakthrough in predicting the prognosis of triple-negative breast cancer (TNBC), a particularly aggressive disease. Their research, published in JCO Precision Oncology as part of the TOWARDS study, has …
Chemical screen identifies PRMT5 as therapeutic target for paclitaxel-resistant triple-negative breast cancer
By: Liu Jia, Chinese Academy of Sciences From: medicalxpress.com In a study published in Cell Chemical Biology, a research team led by Prof. Tan Weihong and Prof. Wu Qin from the Hangzhou Institute of Medical of the Chinese Academy of Sciences has identified protein arginine methyltransferases (PRMTs), crucial regulators of RNA splicing and chromatin stability, as a new therapeutic target …